Yohannes Belay*, Bamlaku Enawgaw , Feyissa Challa , Meron Sileshi, Amha Gebremedhin and Ketsela Yirdaw
Background Tumor lysis syndrome is one of a catastrophic cŽn?ŝ?ŝŽn of mƵů?ŝ?ů? metabolic derangements that occur in bulk and rapidly dividing cancer. It is most commonly associated with hematological malignancies and results in ƐŝŐnŝĨŝc?n? mortality and morbidity. The aim of this study was to determine the incidence and factors ?r??ŝc?ŝnŐ laboratory tumor lysis syndrome in ???ŝ?n?Ɛ with hematological malignancies. Methods A ?rŽƐ??c?ŝv? cohort study was conducted on 49 ???ŝ?n?Ɛ diagnosed with hematological malignancies at Tikur Anbessa specialized hospital from September 2017 to April 2018. Data and blood sample were collected ?Ĩ??r Ő???ŝnŐ wrŝ???n informed consent from the ???ŝ?n?Ɛ? Laboratory tumor lysis syndrome was assessed based on the Cairo and Bishop ??Ĩŝnŝ?ŝŽn criteria using daily measured laboratory values of uric acid, potassium, phosphate and calcium. A regression analysis was used to assess the Ɛ???ŝƐ?ŝc?ů ?ƐƐŽcŝ??ŝŽn between incidence and factors ?r??ŝc?ŝnŐ laboratory tumor lysis syndrome. Results The incidence of laboratory tumor lysis syndrome (LTLS) was 30.6% with 4.1% spontaneous and 26.5% new onset of LTLS. White blood cell count ≥ 25x109/L (AOR: 5.47, 95% CI: 1.11-26.96), lactate dehydrogenase level ≥2 ?ŝm?Ɛ upper limit normal (AOR: 8.97, 95 % CI: 1.73-46.45)and age ≥ 60 years (AOR: 8.75, 95 % CI: 1.27-60.56) were independent factors ?r??ŝc?ŝnŐ LTLS. Conclusion More than one-fourth of ????n?Ɛ with hematological malignancies developed LTLS. Increased baseline white blood cell count, lactate dehydrogenase level and age were the main factors ?r??ŝc?ŝnŐ LTLS. Keywords: Tumor lysis syndrome; Hematological malignancy; Incidence; White blood cell count.
